CRBU

$1.97

Market ClosedAs of Mar 17, 8:00 PM UTC

Caribou Biosciences, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.97
Potential Upside
5%
Whystock Fair Value$2.07
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editin...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$190.38M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.55
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-78.97%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
5.60

Recent News

Zacks
Mar 16, 2026

Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?

Here is how CareCloud, Inc. (CCLD) and Caribou Biosciences, Inc. (CRBU) have performed compared to their sector so far this year.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Mar 14, 2026

Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference

Executives from Caribou Biosciences (NASDAQ:CRBU) outlined upcoming clinical, regulatory, and financing milestones for its allogeneic cell therapy pipeline during a discussion at the Leerink Global Healthcare Conference in Miami. Management focused on plans to advance its lead program, vispa-cel, in

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 5, 2026

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +14.11% and +56.02%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 4, 2026

EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates

EyePoint (EYPT) delivered earnings and revenue surprises of -3.85% and +15.89%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 2, 2026

Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of +18.18% and +6.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.